Read More Pharma Industry News Gyre Therapeutics enrolls 272 patients in late-stage pirfenidone study targeting China’s pneumoconiosis crisis Gyre Therapeutics completes enrollment of 272 patients in its Phase 3 pirfenidone trial for pneumoconiosis—find out how it could change treatment in China. bySoujanya RaviOctober 15, 2025